Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-Blind Comparison of LY900014 and Fiasp®, Both in Combination with Basal Insulin in Adults with Type 1 Diabetes, PRONTO-Compare

Trial Profile

A Prospective, Randomized, Double-Blind Comparison of LY900014 and Fiasp®, Both in Combination with Basal Insulin in Adults with Type 1 Diabetes, PRONTO-Compare

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin lispro (Primary) ; Insulin aspart
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PRONTO-Compare
  • Sponsors Eli Lilly and Company (India) Pvt. Ltd
  • Most Recent Events

    • 15 Nov 2018 This trial has been Discontinued in Austria, according to European Clinical Trials Database.
    • 08 Nov 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top